Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H13NO4 |
| Molecular Weight | 211.2145 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
InChI
InChIKey=CJCSPKMFHVPWAR-SNVBAGLBSA-N
InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m1/s1
| Molecular Formula | C10H13NO4 |
| Molecular Weight | 211.2145 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
D-Methyldopa is an inactive isomer of methyldopa. It is known, that only L-isomer has the ability to inhibit dopa decarboxylase and possesses the antihypertensive activity in man. Moreover, about twice the dose of the racemate (DL-form of methyldopa) is required for the equal antihypertensive effect.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:52:11 GMT 2025
by
admin
on
Mon Mar 31 21:52:11 GMT 2025
|
| Record UNII |
8K91SZC8W9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
NCT00976235
Created by
admin on Mon Mar 31 21:52:11 GMT 2025 , Edited by admin on Mon Mar 31 21:52:11 GMT 2025
|
PRIMARY | |||
|
DTXSID50859484
Created by
admin on Mon Mar 31 21:52:11 GMT 2025 , Edited by admin on Mon Mar 31 21:52:11 GMT 2025
|
PRIMARY | |||
|
8K91SZC8W9
Created by
admin on Mon Mar 31 21:52:11 GMT 2025 , Edited by admin on Mon Mar 31 21:52:11 GMT 2025
|
PRIMARY | |||
|
2799-15-7
Created by
admin on Mon Mar 31 21:52:11 GMT 2025 , Edited by admin on Mon Mar 31 21:52:11 GMT 2025
|
PRIMARY | |||
|
721860
Created by
admin on Mon Mar 31 21:52:11 GMT 2025 , Edited by admin on Mon Mar 31 21:52:11 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
IMT-002 (D-MDOPA) is an oral small molecule drug being developed to treat T1D in patients with the HLA-DQ8 gene. When HLA-DQ8 function is inhibited, the immune system will no longer attack insulin producing beta-cells,
|
